E2 ModeratePreliminaryPEM ?ObservationalPeer-reviewedReviewed
Off label use of Aripiprazole shows promise as a treatment for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): a retrospective study of 101 patients treated with a low dose of Aripiprazole.
Crosby, L D, Kalanidhi, S, Bonilla, A et al. · Journal of translational medicine · 2021 · DOI
Quick Summary
This study looked back at medical records of 101 ME/CFS patients who were prescribed a low dose of aripiprazole, a medication typically used for other conditions. The researchers found that some patients reported improvements in their symptoms. While these results are encouraging, the study design means we need to be cautious about how much weight to give these findings.
Why It Matters
ME/CFS lacks FDA-approved treatments and patients often struggle with debilitating fatigue and post-exertional malaise. Any potential therapeutic avenue warrants investigation, and this study suggests aripiprazole may deserve further scrutiny in rigorous clinical trials to determine if it could help some patients.
Observed Findings
- 101 ME/CFS patients received low-dose aripiprazole treatment
- Some patients reported subjective symptomatic improvement
- No serious adverse events were reported in the cohort
- The medication was used off-label, indicating it is not an approved ME/CFS treatment
Inferred Conclusions
- Aripiprazole may show promise as a potential off-label treatment for some ME/CFS patients
- Low-dose aripiprazole was generally well-tolerated in this patient population
- Further investigation through controlled trials is warranted
Remaining Questions
- What proportion of patients experienced clinically meaningful improvement, and what were the specific symptom domains affected?
- How do outcomes in aripiprazole-treated patients compare to matched controls or placebo?
- What is the optimal dosing regimen and duration of treatment?
- Which patient characteristics predict positive response to aripiprazole therapy?
What This Study Does Not Prove
This study does not prove that aripiprazole causes symptom improvement in ME/CFS patients. It is observational without a control group, so improvements could be due to placebo effect, natural disease fluctuation, concurrent treatments, or other unmeasured factors. Larger, randomized controlled trials would be needed to establish true efficacy.
Tags
Method Flag:PEM_UNCLEARWeak Case DefinitionNo ControlsExploratory Only
Symptom:Cognitive DysfunctionFatigue